Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Vaccine. 2015 Jun 10;33(31):3709–3716. doi: 10.1016/j.vaccine.2015.05.091

Table 4.

Human predicted survival probability at month 7 using the single correlate peak anti-PA IgG and ED50 models.

Peak anti-PA IgG
 Peak ED50
754-IM
 754-IM
Time point (Months) NHP N Human N % Survival (95% CI) Human N % Survival (95% CI)
7 137 636 83.4 (76.2–89.2) 289 79.3 (72.1–85.7)

The human and NHP studies have been described in detail previously [9,10]. Predicted % survival in human cohorts based on the NHP peak anti-PA IgG model. The 7-IM, 5-IM and 4-IM groups were combined as 754-IM since they received the same treatment at this month 7 time point. Confidence intervals (95% CI) are in parentheses.